April 23rd 2024
Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Study Explores Racial/Ethnic Disparities in Incidence of Breast Cancer Subtypes
May 16th 2014An analysis of a large, nationwide dataset has revealed that regardless of their socioeconomic status, black women are nearly twice as likely to be diagnosed with triple-negative breast cancer (TNBC) and Asian/Pacific Islander women are more likely to be diagnosed with HER2-overexpressing breast cancer compared with white women.
Web-Based Program Helps Patients and Survivors to Manage Sexual Side Effects
May 15th 2014Sexual problems, such as loss of desire, failure to get aroused easily, and vaginal dryness and pain during sexual activity, are prevalent among breast cancer survivors, and they rarely go away without treatment.
Orientation Eases Stress and Helps Breast Cancer Patients Manage Neoadjuvant Regimens
May 8th 2014Nurses at the Rutgers Cancer Institute of New Jersey have developed a program to help patients with early-stage breast cancer to better understand and retain information about their presurgical treatments.
Archana Ajmera on Stomatitis Prevention During Metastatic Breast Cancer Treatment
May 3rd 2014Archana Ajmera, RN, MSN, WHNP-BC, ANP-BC, nurse practitioner, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses stomatitis prevention during everolimus/exemestane treatment for metastatic breast cancer.
Evidence-Based Approaches to Survivorship Care
April 30th 2014The number of cancer survivors in the United States is approaching 14 million, but that good news also means more attention must be paid to quality-of-life concerns for these individuals, as well as any long-term after effects of treatment.
USPSTF, ASCO Issue More Guidance on Genetic Testing Based on Family History
April 24th 2014Oncology practitioners now have several resources to consult for advice on genetic testing for their patients following the US Preventive Services Task Force (USPSTF) December 2013 update of its 2005 BRCA recommendations, plus new recommendations from the American Socieity of Clinical Oncology (ASCO) announced in February and published in the Journal of Clinical Oncology.
Helping Patients to Make Informed Decisions About Fertility Preservation
April 23rd 2014Studies show that young women diagnosed with breast cancer are not routinely receiving information about fertility preservation (FP) before their anticancer therapy begins, posing a missed opportunity for healthcare practitioners to provide women with options for improving their chances for a future pregnancy.
Leslie R. Schover on Vaginal Dryness and Pain in Breast Cancer Patients Treated With AIs
April 17th 2014Leslie R. Schover, PhD, clinical psychiatrist, professor, behavioral science, The University of Texas MD Anderson Cancer Center, discusses vaginal dryness and pain in patients with breast cancer treated with aromatase inhibitors.
Breast Cancer Patients Fare Worse When Adjuvant Chemotherapy Is Delayed
April 14th 2014Breast cancer patients whose chemotherapy is initiated more than 60 days following surgery experience worse survival outcomes, and the impact of treatment delay is greatest among patients with stage III or triple-negative breast cancer and those whose HER2-positive tumors have been treated with trastuzumab
Updated Findings Show Palbociclib Improves PFS, not OS
April 7th 2014Palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, more than doubled progression-free survival (PFS) when used in combination with letrozole for patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer
New Study Shows Fertility Drugs Do Not Increase Breast Cancer Risk, Monitoring Still Warranted
April 3rd 2014Women who took the fertility drugs clomiphene citrate (Clomid) or gonadotropins did not experience an increased risk for breast cancer compared with women who were not treated with those medications, according to a 30-year follow-up study published in the April issue of Cancer Epidemiology, Biomarkers & Prevention.
Dr. Schover on the Web-Based Intervention "Tendrils" for Breast Cancer Survivors
March 28th 2014Leslie R. Schover, PhD, clinical psychiatrist, professor, behavioral science, The University of Texas MD Anderson Cancer Center, discusses the web-based intervention Tendrils: Sexual Renewal and Motherhood after Cancer.
Phone Application Helps Endometrial and Breast Cancer Survivors Lose Weight
March 28th 2014Early-stage overweight endometrial and breast cancer survivors had moderate success in lowering their body mass index (BMI) and waste circumference after using the web and smart phone/tablet–based weight loss application "Lose It!"
Anastrozole Found to Prevent Breast Cancer in High-Risk Postmenopausal Women
March 21st 2014Findings from the International Breast Cancer Intervention Study II (IBIS II) examining the efficacy of the aromatase inhibitor anastrozole as a breast cancer preventive show that the oral agent provided significant benefit to postmenopausal women deemed at high risk
Select Older Patients Can Avoid Radiation After Breast-Conserving Surgery
March 18th 2014A subgroup of older breast cancer patients may be able to forgo radiation therapy (RT) after breast-conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence
Exercise Reduces Joint Pain in Breast Cancer Patients Treated With Aromatase Inhibitors
March 13th 2014A new study reported at the 2013 San Antonio Breast Cancer Symposium shows that a prescribed exercise program reduces joint pain in breast cancer survivors taking aromatase inhibitors (AIs), with pain reductions observed at all levels of exercise.
Preventive Prophylactic Oophorectomy Should be performed by age 35 for women with BRCA1 mutations.
February 25th 2014International researchers from seven countries conducted a prospective study to determine risk reduction of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy and examine other factors, such as impact of this procedure on mortality and five year survival.